A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma

Clin Adv Hematol Oncol. 2005 Jun;3(6):468-72; discussion 472-4.

Authors

Dustin A Deming¹, Amy L Stella, Kyle D Holen, Geoffrey Ku, Eileen M O'Reilly

Affiliation

¹ University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave., Madison, Wisconsin 53792-5666, USA.

PMID: 16167024

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Hormonal / administration & dosage*
Carcinoma, Hepatocellular / complications
Carcinoma, Hepatocellular / diagnostic imaging
Carcinoma, Hepatocellular / drug therapy*
Dyspnea / complications
Dyspnea / diagnostic imaging
Dyspnea / drug therapy*
Hepatitis C / complications
Hepatitis C / diagnostic imaging
Hepatitis C / drug therapy*
Humans
Injections, Intramuscular
Liver Cirrhosis
Liver Neoplasms / complications
Liver Neoplasms / diagnostic imaging
Liver Neoplasms / drug therapy*
Lung Neoplasms / complications
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / secondary
Male
Middle Aged
Octreotide / administration & dosage*
Radiography

Substances

Antineoplastic Agents, Hormonal
Octreotide